Jagsonpal Pharmaceuticals Limited has informed the Exchange about Presentation
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagsonpal Pharmaceuticals reported H1FY26 revenue of ₹1,501 Mn, up 10.2% YoY, while Q2FY26 revenue was nearly flat at ₹745 Mn due to GST 2.0 transition adjustments that led to temporary moderation in sales. Operating EBITDA margins contracted slightly (-31 to -39 bps YoY), but PAT surged 39.2% YoY in H1 to ₹234 Mn with margins expanding 324 bps to 15.6%, helped by lower ESOP costs and higher other income. The company holds a strong cash balance of ₹1,604 Mn as of Sep 30, 2025, and paid out ₹166 Mn as dividend at 125% (₹2.5 per share). Jagsonpal strengthened its leadership team by appointing Amrut Medhekar as COO and Nirav Vora as CFO. Management reiterated its three-pronged growth strategy — 4-6 new product launches annually, volume growth via sales force, and inorganic acquisitions — to accelerate growth in H2FY26.
Shareholders see strong H1 profit growth and a healthy cash-rich balance sheet supporting dividends and future acquisitions, though flat Q2 revenue and slightly weaker EBITDA margins may temper near-term sentiment. New senior leadership and a clear growth roadmap could be positive for long-term investors.